Pioglitazone reduces mortality and adverse events in patients with type 2 diabetes and with advanced chronic kidney disease: National cohort study

Chieh Li Yen; Chao Yi Wu; Lai Chu See; Yi Jung Li; Min Hua Tseng; Wei Sheng Peng; Jia Rou Liu; Yung Chang Chen; Tzung Hai Yen; Ya Chung Tian; Chih Wei Yang; Gerard F. Anderson; Huang Yu Yang

doi:10.2337/dc20-1584

Pioglitazone reduces mortality and adverse events in patients with type 2 diabetes and with advanced chronic kidney disease: National cohort study

Chieh Li Yen, Chao Yi Wu, Lai Chu See, Yi Jung Li, Min Hua Tseng, Wei Sheng Peng, Jia Rou Liu, Yung Chang Chen, Tzung Hai Yen, Ya Chung Tian, Chih Wei Yang, Gerard F. Anderson, Huang Yu Yang

Bloomberg School of Public Health

Research output: Contribution to journal › Letter › peer-review

Original language	English (US)
Pages (from-to)	e152-e153
Journal	Diabetes care
Volume	43
Issue number	10
DOIs	https://doi.org/10.2337/dc20-1584
State	Published - Oct 2020

ASJC Scopus subject areas

Internal Medicine
Endocrinology, Diabetes and Metabolism
Advanced and Specialized Nursing

Access to Document

10.2337/dc20-1584

Cite this

Yen, C. L., Wu, C. Y., See, L. C., Li, Y. J., Tseng, M. H., Peng, W. S., Liu, J. R., Chen, Y. C., Yen, T. H., Tian, Y. C., Yang, C. W., Anderson, G. F., & Yang, H. Y. (2020). Pioglitazone reduces mortality and adverse events in patients with type 2 diabetes and with advanced chronic kidney disease: National cohort study. Diabetes care, 43(10), e152-e153. https://doi.org/10.2337/dc20-1584

@article{7a817ff338d74d3ebf38021c0d7c78af,

title = "Pioglitazone reduces mortality and adverse events in patients with type 2 diabetes and with advanced chronic kidney disease: National cohort study",

author = "Yen, {Chieh Li} and Wu, {Chao Yi} and See, {Lai Chu} and Li, {Yi Jung} and Tseng, {Min Hua} and Peng, {Wei Sheng} and Liu, {Jia Rou} and Chen, {Yung Chang} and Yen, {Tzung Hai} and Tian, {Ya Chung} and Yang, {Chih Wei} and Anderson, {Gerard F.} and Yang, {Huang Yu}",

note = "Funding Information: Funding. This study was supported by grants from Chang Gung Memorial Hospital (CORPG5J0041, CMRPG3K0041, CLRPG3D0046). Duality of Interest. No potential conflicts of interest relevant to this article were reported. Author Contributions. H.-Y.Y., L.-C.S., and G.F.A. contributed to study concept and design. L.-C.S., M.-H.T., W.-S.P., J.-R.L., Y.-C.C., Y.-C.T., and C.-L.Y. contributed to acquisition, analysis, and interpretation of data. C.-L.Y. and C.-Y.W. drafted the manuscript. L.-C.S., Y.-J.L., T.-H.Y., Y.-C.T., and C.-W.Y. contributed to critical revision. L.-C.S., W.-S.P., J.-R.L., and G.F.A. performed the statistical analysis. H.Y.Y. and L.C.S. are the guarantors of this work and, as such, had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.",

year = "2020",

month = oct,

doi = "10.2337/dc20-1584",

language = "English (US)",

volume = "43",

pages = "e152--e153",

journal = "Diabetes care",

issn = "0149-5992",

publisher = "American Diabetes Association Inc.",

number = "10",

}

TY - JOUR

T1 - Pioglitazone reduces mortality and adverse events in patients with type 2 diabetes and with advanced chronic kidney disease

T2 - National cohort study

AU - Yen, Chieh Li

AU - Wu, Chao Yi

AU - See, Lai Chu

AU - Li, Yi Jung

AU - Tseng, Min Hua

AU - Peng, Wei Sheng

AU - Liu, Jia Rou

AU - Chen, Yung Chang

AU - Yen, Tzung Hai

AU - Tian, Ya Chung

AU - Yang, Chih Wei

AU - Anderson, Gerard F.

AU - Yang, Huang Yu

N1 - Funding Information: Funding. This study was supported by grants from Chang Gung Memorial Hospital (CORPG5J0041, CMRPG3K0041, CLRPG3D0046). Duality of Interest. No potential conflicts of interest relevant to this article were reported. Author Contributions. H.-Y.Y., L.-C.S., and G.F.A. contributed to study concept and design. L.-C.S., M.-H.T., W.-S.P., J.-R.L., Y.-C.C., Y.-C.T., and C.-L.Y. contributed to acquisition, analysis, and interpretation of data. C.-L.Y. and C.-Y.W. drafted the manuscript. L.-C.S., Y.-J.L., T.-H.Y., Y.-C.T., and C.-W.Y. contributed to critical revision. L.-C.S., W.-S.P., J.-R.L., and G.F.A. performed the statistical analysis. H.Y.Y. and L.C.S. are the guarantors of this work and, as such, had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

PY - 2020/10

Y1 - 2020/10

UR - http://www.scopus.com/inward/record.url?scp=85091470275&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85091470275&partnerID=8YFLogxK

U2 - 10.2337/dc20-1584

DO - 10.2337/dc20-1584

M3 - Letter

C2 - 32801131

AN - SCOPUS:85091470275

SN - 0149-5992

VL - 43

SP - e152-e153

JO - Diabetes care

JF - Diabetes care

IS - 10

ER -

Pioglitazone reduces mortality and adverse events in patients with type 2 diabetes and with advanced chronic kidney disease: National cohort study

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this